1. Objectives: To evaluate the pathologic response, treatment complications, and overall survival in patients with cervical cancer who are treated by neo-adjuvant chemotherapy and surgery. 2. Design: The study is single-grouped, non-blinded, one-centered, and in phase two of clinical trials. 3. Setting and conduct: A total of 30 patients will be selected by convenience sampling method from patients treated in the Radiation Oncology Ward of Imam Reza Hospital in Mashhad. 4. Major inclusion criteria: women aged between 18 and 70 years; definitive pathologic diagnosis of squamous cell carcinoma; and being in stages IB2, IIA2, and IIB according to the International Federation of Gynecology and Obstetrics classification. Main exclusion criteria: history of injection of chemotherapy drug during the four weeks preceding the study; and serious comorbidities such as cardiac disease, poorly controlled diabetes mellitus, malignant hypertension, or bleeding tendency. 5. Intervention: Pretreatment evaluation includes examination, pelvic magnetic resonance imaging, abdominal sonography, and chest x-ray. Patients receive three one-week periods of neo-adjuvant chemotherapy with paclitaxel (135 milligrams per square meter) on day 1 and cisplatin (75 milligrams per square meter) on day 2 every three weeks for three cycles. Patients without desirable response to chemotherapy will undergo standard pelvic chemoradiotherapy. In case the disease worsens in the 4 to 6 weeks later, the patient will undergo Wertham surgery along with three further chemotherapy cycles. The patients will be candidate for postoperative adjuvant radiation in case they have positive surgical margins, lymph nodes or parametric involvement, or at least two of the following factors: deep stromal invasion, lymphovascular invasion, or size greater than 4 centimeters in the histopathology report of the surgical specimen. 6. Main outcome measures: Pathologic response of the tumor to treatment will be assessed at the first presentation, after each cycle, and after surgery. Complication of chemoradiotherapy (e.g., nausea, vomit, neutropenia, edema, and neauropathy) will be evaluated after each cycle. Overall survival will be assessed one year after initiation of intervention.